Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease

Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease

BackgroundTolvaptan (TV) is the first vasopressin-receptor antagonist approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). No publications report TV experience in real clinical practice during the first year of treatment.MethodsA prospective study of an initial cohort...

Full description

Bibliographic Details
Main Authors:	Javier Naranjo, Francisco Borrego, José Luis Rocha, Mercedes Salgueira, Maria Adoración Martín-Gomez, Cristhian Orellana, Ana Morales, Fernando Vallejo, Pilar Hidalgo, Francisca Rodríguez, Remedios Garófano, Isabel González, Rafael Esteban, Mario Espinosa
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Medicine
Subjects:	glomerular filtration rate (eGFR) hepatic toxicity polycystic kidney disease (PKD) tolvaptan urinary osmolality
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2022.987092/full

Similar Items

Clinical and genetic characteristics of Korean autosomal dominant polycystic kidney disease patients
by: Yun Kyu Oh, et al.
Published: (2021-07-01)

Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?
by: Hee Sun Beak, et al.
Published: (2023-12-01)

Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?
by: Fei Liu, et al.
Published: (2021-07-01)

Magnetic resonance imaging is effective for evaluating the therapeutic effect of tolvaptan on total kidney volume in patients with autosomal dominant polycystic kidney disease
by: Shuma Hirashio, et al.
Published: (2018-06-01)

Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
by: Yaerim Kim, et al.
Published: (2023-05-01)

Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
by: Kyohei Kunizawa, et al.
Published: (2018-03-01)

Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
by: Sans-Atxer L, et al.
Published: (2018-01-01)

Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease
by: Hiroki Mizuno, et al.
Published: (2017-07-01)

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis
by: Michael Lioudis, et al.
Published: (2023-06-01)

The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis
by: Xuanwei Li, et al.
Published: (2023-11-01)

The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis
by: Xuanwei Li, et al.
Published: (2023-11-01)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
by: Raina R, et al.
Published: (2022-09-01)

Are you ready to accompany autosomal dominant polycystic kidney disease patients in their treatment journey? Real practice for selecting rapid progressors and treatment with tolvaptan
by: Yeonsoon Jung, et al.
Published: (2023-06-01)

Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients
by: Shinya Nakatani, et al.
Published: (2020-02-01)

Effects of tolvaptan on renal function in chronic kidney disease patients with volume overload
by: Suzuki S, et al.
Published: (2018-08-01)

Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD
by: Eiji Higashihara, et al.
Published: (2022-02-01)

Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling
by: Xia Zhou, et al.
Published: (2022-09-01)

Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease
by: Djalila Mekahli, et al.
Published: (2023-02-01)

Autosomal dominant polycystic kidney disease: updated perspectives
by: Rastogi A, et al.
Published: (2019-08-01)

Treatment persistence to tolvaptan in patients with autosomal dominant polycystic kidney disease: a secondary use of data analysis of patients in the IMADJIN® dataset
by: Mark Thomas, et al.
Published: (2021-12-01)

Novel Mutations in the PKD1 and PKD2 Genes of Chinese Patients with Autosomal Dominant Polycystic Kidney Disease
by: Dechao Xu, et al.
Published: (2018-03-01)

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4
by: Olivier Devuyst, et al.
Published: (2017-11-01)

Echocardiographic Findings and Genotypes in Autosomal Dominant Polycystic Kidney Disease
by: Ryohei Miyamoto, et al.
Published: (2021-11-01)

Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period
by: Hyuk Huh, et al.
Published: (2023-03-01)

PKD1-associated autosomal dominant polycystic kidney disease with glomerular cysts presenting with nephrotic syndrome caused by focal segmental glomerulosclerosis
by: Yasuhiro Oda, et al.
Published: (2019-08-01)

Emerging Therapies for Childhood Polycystic Kidney Disease
by: William E. Sweeney, et al.
Published: (2017-04-01)

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial
by: Muto S, et al.
Published: (2017-10-01)

Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment
by: Barnawi RA, et al.
Published: (2018-02-01)

Autosomal dominant polycystic kidney disease: an update on epidemiological and molecular aspects
by: Everton F. Alves, et al.
Published: (2015-12-01)

Mutation Analysis of Autosomal-Dominant Polycystic Kidney Disease Patients
by: Yasuo Suzuki, et al.
Published: (2023-02-01)

Differential Expression of -Associated Genes in Autosomal Dominant Polycystic Kidney Disease
by: Yeon Joo Yook, et al.
Published: (2012-03-01)

Genetic analysis of 3 pedigrees with autosomal dominant polycystic kidney disease
by: LOU Guiyu, et al.
Published: (2021-10-01)

Gene Panel Analysis in a Large Cohort of Patients With Autosomal Dominant Polycystic Kidney Disease Allows the Identification of 80 Potentially Causative Novel Variants and the Characterization of a Complex Genetic Architecture in a Subset of Families
by: Vilma Mantovani, et al.
Published: (2020-05-01)

Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy
by: Mai Yamazaki, et al.
Published: (2024-02-01)

Dietary Aspects and Drug-Related Side Effects in Autosomal Dominant Polycystic Kidney Disease Progression
by: Borja Quiroga, et al.
Published: (2022-11-01)

Genetics of Autosomal Recessive Polycystic Kidney Disease and Its Differential Diagnoses
by: Carsten Bergmann, et al.
Published: (2018-02-01)

A single-center analysis of genotype–phenotype characteristics of Chinese patients with autosomal dominant polycystic kidney disease by targeted exome sequencing
by: Ziyan Yan, et al.
Published: (2022-09-01)

A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease
by: Gregory Mader, et al.
Published: (2022-10-01)

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model
by: Hayley Bennett, et al.
Published: (2019-04-01)

Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
by: Yeshwanter Radhakrishnan, et al.
Published: (2022-07-01)